drugset
drugset / Trial / NCT06048692

Cefepime and Unictam on Preventing Post-Cesarean Surgical Site Infections

NCT06048692 ↗

Phase 3 Unknown 213 enrolled Beni-Suef University
RandomizedParallel-groupSingle-blindPrevention

Summary

the aim of this study is to evaluate the efficacy of employing cefepime (CFM) versus ampicillin/sulbactam (AMS) in lowering the rate of post-cesarean surgical site infections.

Timeline

Start
2023-01-01
Primary completion
2023-09-15
Completion
2023-09-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ampicillin Unknown 1500 mg Intravenous
Subject Cefepime Small molecule 1000 mg Intravenous

Indications

No indication recorded.